首页|Biological variation in clozapine and metabolite reporting during therapeutic drug monitoring
Biological variation in clozapine and metabolite reporting during therapeutic drug monitoring
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Elsevier
? 2022 Elsevier B.V.Background: Clozapine (CLO) is an atypical antipsychotic used in management of treatment-resistant schizophrenia. Adverse drug reactions are caused by both CLO and its primary metabolite, norclozapine (NCLO). We defined the biological variability of CLO, NCLO, and the CLO to NCLO ratio (CNR) as well as assess the impact of reporting CLO and NCLO routinely. Methods: The CVi and CVg were calculated from 1904 results from 247 patients by CV-ANOVA, and ANOVA, respectively, for CLO, NCLO, and the CNR. Association between each were also analyzed against a number of parameters including age and gender, complete blood count (CBC), kidney and liver function tests, lipids, and glucose within 24 h of CLO measurement. Results: For CLO, NCLO and CNR, the CVi was calculated as 19.3%, 19.2%, and 14.7%, and the CVg was 46.9%, 51.4%, and 36.3%, respectively. A total of 87 patients (19.7%) demonstrated higher NCLO results than CLO, with a ratio as low as 0.47. Kidney function was also found to have a statistically significant relationship to CLO and NCLO levels. Conclusions: We provide data for biological variability of CLO metabolism as well as while providing some evidence for reporting NCLO values clinically.
Adverse drug reactionsAnalytical quality targetsBiological variationClozapineNorclozapineTherapeutic drug monitoring
Wickramarachchi P.、Boyd J.M.、Orton D.J.
展开 >
Department of Neuroscience University of Calgary
Department of Pathology & Laboratory Medicine Cumming School of Medicine University of Calgary and
NSTL
Elsevier
